Novaremed
Novaremed AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, established in 2008. The company focuses on developing innovative treatments for neuropathic pain through its proprietary drug candidate, NRD.E1. This orally active, non-opioid small molecule features a novel mechanism of action targeting podoplanin (PDPN) as a tyrosine kinase modulator. By advancing this therapeutic approach, Novaremed aims to provide effective solutions for neuropathy-related conditions, particularly diabetic neuropathic pain, enhancing treatment options for healthcare professionals and patients alike.
Metys Pharmaceuticals focuses on developing MP-101, a small molecule drug aimed at preventing and treating chemotherapy-induced peripheral neuropathy, a common and distressing side effect of cancer treatments. MP-101 acts as an orally-active modulator of glutamate signaling in the spine and brain, making it a promising candidate for addressing various central nervous system disorders, including depression, cognitive impairment, and neuropathic pain. The drug is a patent-pending non-racemic mixture of the enantiomers of dimiracetam, specifically designed to enhance potency beyond traditional racemic mixtures. Metys Pharmaceuticals has secured worldwide exclusive rights to racemic dimiracetam from Neurotune AG, along with relevant regulatory data, to support future clinical trials for MP-101. The company aims to leverage its findings to provide effective neuropathic pain treatments for patients undergoing chemotherapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.